Capital Cell continues to invest in Biomedicine

08/10/2020
Diego Gutiérrez
Capital Cell continues to invest in Biomedicine

Capital Cell is Europe's first online investment platform specialising in biomedicine. Despite the global coronavirus pandemic, it has raised 4 million euros of investment for 4 companies in the first quarter of 2020. The coronavirus crisis is hitting the global economy hard, especially in our country. 

After a tough quarter for the markets, investment funds have opted to bet on biomedical high-tech companies, a sector in full bloom in Spain. This is the case of Cell Capital. 

Biotechnology, the only sector to be spared 

According to Capital Cell CEO Daniel Oliver"In a context such as the current one, the importance of biotechnology goes from being strategic to being urgent, and it is going to establish itself as one of the most desirable investment sectors". The investment made by Capital Cell alone would represent more than 12% of the total investment made in the biotechnology sector in Spain in 2018, which amounted to €98 million according to the Spanish Association of Biotechnology Companies. 

However, it is not only Spain that is seeing growth in biotechnology investment. Between February and March, the biotech sector yielded the highest return on investment on the US NASDAQ index, while most investment sectors, including financial, energy and real estate, recorded historic collapses. 

Capital Cell doesn't miss a beat 

The online investment platform specialising in biomedicine invested four million euros in four companies in the biotech sector in the first quarter of this year, which is 37% more than in the same period last year. It is also more than a third of the total invested last year, as €11.6m was moved in 2019. 

For example, since the start of the Covid-19 crisis confinement, Capital Cell has successfully launched and closed a ¤560,000 investment round for Valencian digital diagnostic system companyeKuore. Also other start-ups such asAortyx,DevicareoAbility Pharma6 million have been confirmed. 

Lastest news

The State of Technology M&A in Spain | October 2026 analysis

En octubre de 2026 hubo 37 operaciones de M&A tecnológico en España: 16 fueron adquisiciones corporativas, inversiones de private equity, fusiones o tomas de participación, y 21 fueron rondas de venture capital. El 62,2% de las operaciones (23 de 37) fueron...

Webinar | How much does your business depend on you?

IMPORTANT INFORMATION: Registration for and participation in the webinars are completely anonymous to third parties. If, for a month, you were unable to have a say in important decisions, what would happen in your company? Your company can grow, be profitable and have good...

Notable technology M&A deals in Spain | September 2026 Analysis

Technology M&A in Spain totalled 61 identified transactions by the end of September 2026, the highest figure in the monthly series we have been publishing since May. Of these, 41 were acquisitions, private equity investments, asset purchases, joint ventures or takeovers...

Baker Tilly advises Invelon on the acquisition of byAR

In September 2026, Invelon, a Spanish technology company specialising in virtual, augmented and mixed reality, completed the acquisition of a majority stake in byAR, a Portuguese company specialising in museum exhibitions and the development of spaces...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?